Michael D Lock

US Patent:

20190247333, Aug 15, 2019

Filed:

Feb 15, 2019

Appl. No.:

16/277367

Inventors:

- Berkshire, GB
Michael LOCK - Emeryville CA, US
Brooks M. BOYD - Berkeley CA, US

Assignee:

ZOGENIX INTERNATIONAL LIMITED - Berkshire

International Classification:

A61K 31/137
A61K 31/065
A61P 25/08

Abstract:

A method of reducing convulsive seizure frequency in a human patient diagnosed with Dravet syndrome, comprising administering to the patient a therapeutically effective dose of fenfluramine or a pharmaceutically acceptable salt, base, acid or amine thereof, and repeating the administering over a period of days until the patient exhibits a significant reduction (e.g., 40% or greater) from baseline in convulsive seizure frequency. In some embodiments of the method, convulsive seizures are completely eliminated for 10 days or more, 20 days or more, 30 days or more, 50 days or more, 100 days or more.

US Patent:

20190125697, May 2, 2019

Filed:

Sep 24, 2018

Appl. No.:

16/139608

Inventors:

- Berkshire, GB
Michael LOCK - Emeryville CA, US
Brooks M. BOYD - Berkeley CA, US

Assignee:

ZOGENIX INTERNATIONAL LIMITED - Berkshire

International Classification:

A61K 31/137
A61P 25/08
A61K 31/357
A61K 31/19
A61K 31/5513
A61K 31/047

Abstract:

A method of reducing convulsive seizure frequency in a human patient diagnosed with Dravet syndrome, comprising administering to the patient a therapeutically effective dose of fenfluramine or a pharmaceutically acceptable salt, base, acid or amine thereof, and repeating the administering over a period of days until the patient exhibits a significant reduction (e.g., 40% or greater) from baseline in convulsive seizure frequency. In some embodiments of the method, convulsive seizures are completely eliminated for 10 days or more, 20 days or more, 30 days or more, 50 days or more, 100 days or more.

US Patent:

20190091173, Mar 28, 2019

Filed:

Sep 24, 2018

Appl. No.:

16/139617

Inventors:

- Berkshire, GB
Michael LOCK - Emeryville CA, US
Brooks M. BOYD - Berkeley CA, US

Assignee:

ZOGENIX INTERNATIONAL LIMITED - Berkshire

International Classification:

A61K 31/137
A61P 25/08

Abstract:

A method of increasing an average time between seizures in a human patient diagnosed with Dravet syndrome, comprising administering to the patient a therapeutically effective dose of fenfluramine or a pharmaceutically acceptable salt, base, acid or amine thereof, and repeating the administering over a period of days until the patient exhibits an increase from baseline in average time between convulsive seizures of 6 hours, days weeks or more.